Trending Stock News

Agios Pharmaceuticals, Inc. (AGIO) Reaches $89.83 After 5.00% Down Move; PROTEXT MOBILITY (TXTM) Shorts Up By 202.73%

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Logo

PROTEXT MOBILITY INC (OTCMKTS:TXTM) had an increase of 202.73% in short interest. TXTM’s SI was 266,100 shares in June as released by FINRA. Its up 202.73% from 87,900 shares previously. The stock decreased 12.50% or $0.0001 during the last trading session, reaching $0.0007. About 14.35M shares traded. ProText Mobility, Inc. (OTCMKTS:TXTM) has 0.00% since June 4, 2017 and is . It has underperformed by 12.57% the S&P500.

The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is a huge mover today! The stock decreased 7.26% or $7.03 during the last trading session, reaching $89.83. About 901,435 shares traded or 142.01% up from the average. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has risen 88.28% since June 4, 2017 and is uptrending. It has outperformed by 75.71% the S&P500.The move comes after 8 months negative chart setup for the $5.18B company. It was reported on Jun, 4 by Barchart.com. We have $85.34 PT which if reached, will make NASDAQ:AGIO worth $258.75 million less.

Investors sentiment increased to 1.72 in 2018 Q1. Its up 0.50, from 1.22 in 2017Q4. It improved, as 13 investors sold Agios Pharmaceuticals, Inc. shares while 44 reduced holdings. 35 funds opened positions while 63 raised stakes. 52.93 million shares or 15.82% more from 45.70 million shares in 2017Q4 were reported. Invesco Limited stated it has 838,654 shares or 0.03% of all its holdings. Utah Retirement reported 9,200 shares or 0.02% of all its holdings. Balyasny Asset Mngmt Limited Liability Company holds 0.23% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 683,364 shares. Dimensional Fund Lp holds 0% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) or 76,644 shares. Oppenheimer And holds 0.04% or 19,437 shares. Ubs Asset Americas owns 324,752 shares or 0% of their US portfolio. Barclays Public Limited Company accumulated 7,081 shares or 0% of the stock. Jennison Assocs Limited holds 190,752 shares or 0.02% of its portfolio. Principal Financial Grp has 14,895 shares for 0% of their portfolio. International Ca has 16,200 shares. Perceptive Advsrs Lc has 0.57% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Moreover, Renaissance Technology Limited Liability Company has 0.01% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 69,100 shares. Teacher Retirement System Of Texas reported 11,125 shares. State Board Of Administration Of Florida Retirement Sys reported 61,221 shares stake. 6,298 were reported by Citigroup.

Among 19 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 15 have Buy rating, 0 Sell and 4 Hold. Therefore 79% are positive. Agios Pharmaceuticals had 48 analyst reports since July 23, 2015 according to SRatingsIntel. The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) earned “Outperform” rating by Credit Suisse on Thursday, January 21. Canaccord Genuity upgraded Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) rating on Monday, June 13. Canaccord Genuity has “Buy” rating and $90 target. The firm has “Buy” rating by SunTrust given on Sunday, November 19. Oppenheimer upgraded the shares of AGIO in report on Tuesday, January 17 to “Outperform” rating. Janney Capital downgraded the shares of AGIO in report on Monday, June 26 to “Neutral” rating. The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) earned “Buy” rating by J.P. Morgan on Monday, September 18. The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has “Outperform” rating given on Thursday, November 2 by Credit Suisse. The firm has “Buy” rating given on Thursday, June 1 by Oppenheimer. The firm earned “Buy” rating on Wednesday, May 18 by Suntrust Robinson. The firm has “Buy” rating given on Monday, October 24 by Needham.

Analysts await Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) to report earnings on August, 14. They expect $-1.65 earnings per share, up 7.30% or $0.13 from last year’s $-1.78 per share. After $-1.63 actual earnings per share reported by Agios Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 1.23% negative EPS growth.

More notable recent Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare” on May 31, 2018, also Streetinsider.com with their article: “Agios Pharma (AGIO) Highlights ‘Encouraging’ New Data from Phase 1 Study Evaluating Ivosidenib (AG-120) or …” published on June 04, 2018, Benzinga.com published: “Benzinga’s Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO” on June 01, 2018. More interesting news about Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) were released by: Nasdaq.com and their article: “Agios Presents Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced …” published on June 01, 2018 as well as Benzinga.com‘s news article titled: “The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines” with publication date: June 03, 2018.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company has market cap of $5.18 billion. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. It currently has negative earnings. The firm is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings Chart

Leave a Reply

Your email address will not be published. Required fields are marked *